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Abstract
Purpose Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby
increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites
produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the
body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction,
and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between
dietary-AGEs and breast cancer.
Methods We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative
(ER−) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to
reduce circulating AGE levels in ER+ breast cancer survivors.
Results An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of
ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept
study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast
cancer survivors.
Conclusions There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the
potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community
health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.
Keywords Advanced glycation end product · Estrogen receptor · Breast cancer · Tamoxifen resistance · Lifestyle
intervention
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Breast cancer is the 2nd leading cause of new cancer cases
in the US, where more than 3 million breast cancer survivors reside. Lifestyle behaviors such as an unhealthy diet
and physical inactivity are modifiable prognostic factors that
may have distinct molecular consequences on breast cancer
outcomes. Despite a current consensus that exercise and a
healthy diet may improve breast cancer prognosis, little is
known about their positive effects on the biological pathways involved in breast tumor biology.
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Advanced glycation end products (AGEs) are reactive
metabolites produced endogenously as a by-product of sugar
metabolism as well as the oxidation of biological molecules
[1–3]. AGEs irreversibly accumulate in our tissues causing
pathogenic effects on organ homeostasis, genetic fidelity,
protein function, and cell signaling cascades [1–3]. Significantly, an unhealthy diet, high in sugar, fat, and highly processed foods along with a sedentary lifestyle also contribute
to the AGE accumulation pool to contribute to chronic disease development and complications [4–6]. Increases in the
AGE accumulation pool lead to the perpetual activation of
cancer-associated cell signaling cascades including MAPK
(mitogen-activated protein kinase) and AKT (protein kinase
B) leading to aberrant transcriptional activity, immune function, and oxidative stresses [7].
The pathogenic effects of AGEs are often mediated
through activation of the cognate receptor for AGE (RAGE)
[1–3, 6]. RAGE knockdown in ER+ MCF7 cells decreases
17α-ethinyl-estradiol-dependent proliferation and survival through changes in AKT, CCND1 (cyclin D1), and
BCL2 (B-cell lymphoma 2) [8]. AGE-RAGE signaling
promotes the activation of redox-responsive transcription
factors including NFkB (nuclear factor kappa-light-chainenhancer of activated B cells) and AP-1 (activator protein 1)
to increase MAPK and ERK (extracellular signal-regulated
kinase) signaling [9]. Crosstalk between ERα and NFkB
can stimulate cell proliferation and survival and contribute
to tamoxifen resistance [10]. Recent data also indicate that
inhibition of ERα by endocrine therapies such as tamoxifen
may release NFκB from ERα-driven inhibition, possibly
resulting in tamoxifen resistance and NFκB-driven tumor
progression [11]. Additionally, several outcome signatures
derived from women treated with tamoxifen have implicated
immune response as a common mechanism contributing to
tamoxifen resistance [12–14].
Given the common signaling cascades involved in AGE
pathogenesis and ERα regulation, we examined the ability
of AGEs to augment ERα phosphorylation and tamoxifen
resistance, and tested the ability of a defined lifestyle intervention program to lower AGE levels in overweight/obese
post-menopausal women with non-metastatic stage I–III
ER+ breast cancer.

Methods
Retrospective biological samples
For AGE analysis, serum samples were obtained from the
Hollings Cancer Center Tissue Biorepository at the Medical
University of South Carolina (MUSC). In total, 20 well and
20 poorly differentiated serum samples (1 ml of each) were
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selected from female breast cancer patients which had been
stored between 1 and 5 years since diagnosis.
Tissue microarray’s were obtained from US BioMax
(Rockville, MD) and contained 96 samples of non-cancer,
hyperplastic, and cancerous tissue from 48 patients. Pathological data available from each patient included tumor
grade and receptor status. Tissue for mass spectrometry
analysis was obtained from breast cancer patients recruited
in Baltimore hospitals between 1993 and 2003, as previously
described [15, 16].

Immunohistochemical (IHC) staining
IHC staining was performed to examine AGE levels in
tissue as previously published [4]. IHC scores were calculated using the formula: intensity X % positive tumor
cells. Intensity staining was scored as follows: 1—weak,
2—intermediate, 3—strong, and 4—very strong. Percent
positive tumor cells were scored as follows: 1—less than
10%, 2—10–30%, 3—30–60%, and 4—60–100% positive
cells by a pathologist.

AGE ELISA
To examine the levels of AGEs in serum, 96-well format
Oxi-select ELISA’s (Cell Biolabs, San Diego, CA) were
used as directed by the manufacturer. All samples were normalized to total protein concentration [4].

Mass spectrometry analysis
Carboxymethyllysine (CML) and carboxyethyllysine (CEL)
and the internal standards (IS) CML-13C4/CEL-13C4 were
obtained from Sigma-Aldrich/Santa Cruz. The CML/CEL
stock solutions were prepared in water as 1 mg/mL solutions. The CML/CEL calibration standards, 0.8–100 ng/mL,
were prepared by serial dilution of the stocks with PBS.
The working IS solution (10 ng/mL each of the 13C4) was
prepared by diluting the IS stocks with 0.24N trichloroacetic
acid (TCA) solution. The tissue samples were wet weighted
and homogenized in PBS using the Bead Ruptor (Omni),
followed by centrifugation (10 min/16 kg). 15 µL of the tissue supernatant or calibration standards were vortex mixed
with 75 µL IS solution. After centrifugation (10 min/16 kg),
the solutions were transferred to injection vials for LC/MS/
MS. LC was performed with a Shimadzu 20AC-XR system.
The injection volume was 40 µL. Separation was achieved
with a 2 × 150 mm, 3 µm SS-C18 column (Imtakt). Mobile
phase A was 0.1% formic acid in water and mobile phase
B was 50 mM ammonium acetate/80% methanol. The flow
rate was 300 µL/min and peaks were eluted with a 8-min
gradient. MS/MS was performed with a TSQ Vantage triple
quadrupole mass spectrometer (Thermo Fisher Scientific)
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operating in selected reaction monitoring (SRM) mode
with positive electrospray ionization. The target peaks were
detected using the following m/z precursor > product ions:
CML (205 > 84); CML-13C4 (209 > 88); CEL (219 > 84);
CEL-13C4 (223 > 88). CML and CEL in the supernatant (Y
ng/mL) were determined using the Thermo Xcalibur software. Calibration curves, constructed by plotting the peak
area ratios vs. standards, were fitted by linear regressions
(R2 = 0.99). The peak area ratios were calculated by dividing
the peak areas of CML or CEL by the peak area of CML13
C4 or CEL-13C4, respectively.

Cell culture
MCF7 and T47D cell lines were purchased from ATCC
(Manassas, VA). Cells were incubated at 37 °C, 5% CO2
in their respective media. Cells were cultured up to 30 passages before being replaced from low passage stocks. Mycoplasma-negative cultures were ensured by PCR testing. Cells
were monitored throughout with consistent morphology and
doubling-time. T47D cells were incubated in RPMI (Fisher
Scientific, Fair Lawn, NJ) with 10% fetal bovine serum
(Fisher Scientific) and 1% Penicillin/Streptomycin (Fisher
Scientific). MCF7 cells were incubated in DMEM/High
Glucose media (Fisher Scientific) containing 10% FBS and
1% Penicillin/Streptomycin with the following additives: 1%
MEM Non-essential Amino Acids, 1% Sodium Pyruvate, 1%
Sodium Bicarbonate, and 1% insulin (all obtained from Life
Technologies, Grand Island, NY).

Exogenous AGE treatment
Exogenous BSA-AGE and control BSA were produced as
previously published [17]. For examination of AGE treatment, cells (400,000) were seeded into each well of a 6-well
plate in serum-free media overnight before treatment with
AGE metabolite (50ug/ml). Effects of AGE treatment on the
phosphorylation of ERα, AKT, and ERK was assessed by
Western blot as indicated below. Pharmacological targeting
of the MAPK/ERK and PI3K/AKT pathways in the presence of AGE was achieved in serum-free media using the
molecular inhibitors U0126 (ERK) and LY294002 (AKT)
(Cell signaling Technology, Danvers, MA) at a concentration
of 10uM for 12 h before exposure to AGE metabolites. To
examine the effects of AGE metabolite on tamoxifen resistance, cells (3,000) were seeded into each well of a 96-well
plate and were treated with the active metabolite of tamoxifen, 4-hydroxytamoxifen (0, 10 µM) (Sigma-Aldrich, St.
Louis, MO) in combination with varying doses of AGEs
(0, 5 µg/mL, 10 µg/mL, 50 µg/mL). After 24, 48, and 72 h,
SRB staining was used to quantify cell growth as described
previously [18].
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Western Blot analysis
For isolation of total protein, cells at 70–80% confluence
were washed twice with ice cold 1xPBS, and were lysed in
radio-immunoprecipitation assay (RIPA) buffer containing
protease and phosphatase inhibitors (Sigma). Equal amounts
of total protein (50 µg) were resolved by 10% SDS-PAGE
and subjected to Western blot analyses using ECL system (Pierce-Fisher Scientific, Rockford, IL). Total protein
lysates were examined using primary antibodies against
total ERα, phosphorylated ERα-ser118 (p-ERα (ser118)),
phosphorylated ERα-ser167 (p-ERα (ser167)), total ERK,
phosphorylated-ERK (pERK), total AKT, phosphorylatedAKT (pAKT), and GAPDH (all obtained from Cell Signaling Technology).

Intervention design and dietary assessment
See supplementary methods.

Statistical analysis
See supplementary methods.

Results
AGE levels are elevated in ER+ breast cancer
patients
Breast tumor microarrays were stained using antibodies
specific for AGE. Staining intensity in tumor tissue varied
by stage and differentiation (Fig. 1). Highest staining for
epithelial AGE was observed in carcinoma and then hyperplasia tissue when compared to non-cancer tissue specimens (Fig. 1a). In contrast, stromal AGE in the same tissue
samples was highest in non-cancer and hyperplasia tissue
(Fig. 1b). In a separate set of serum samples obtained from
the MUSC biorepository, analysis by ELISA shows that circulating AGE levels are higher in serum from patients with
well-differentiated tumors compared to poorly differentiated
(Fig. 1c). When stratified by ER status, ER+ patients had
significantly higher circulating AGE levels than ER- patients
(Fig. 1d).

Nε‑carboxymethyllysine and Nε‑carboxyethyllysine
are elevated in breast tumors
Levels of CML and CEL were assessed in a separate set of
19 non-cancerous and 18 cancerous breast tissue samples
using liquid chromatography–tandem mass spectrometry
(LC/MS/MS). Compared to non-cancerous tissue, both
CML (Fig. 1e) and CEL (Fig. 1f) levels were elevated in the
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Fig. 1  AGE levels are elevated
in ER+ breast cancer patients.
a Quantification of epithelial
AGE levels in breast normal
and tumor tissue using IHC
staining. b Quantification of
stromal AGE levels in breast
tumor tissue using IHC staining.
c Quantification of circulating AGE levels, analyzed by
ELISA, in serum from breast
cancer patients stratified by
well and poorly differentiated
tumors. d Quantification of circulating AGE levels, analyzed
by ELISA in serum from breast
cancer patients stratified by ER
status. e Quantification of CML
levels in non-cancer and breast
tumor tissue using LC/MS/
MS. f Quantification of CEL
levels in non-cancer and breast
tumor tissue using LC/MS/
MS. g Quantification of CML
levels, analyzed by LC/MS/MS
in non-cancer and breast tumor
tissue stratified by ER status. h
Quantification of CEL levels,
analyzed by LC/MS/MS in noncancer and breast tumor tissue
stratified by ER status

tumor tissues. Average levels of CML and CEL in the tumor
samples were 42.44 ng/µg and 18.55 ng/µg, respectively,
compared to 21.29 ng/µg and 9.468 ng/µg in non-cancerous
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tissue. When stratified by ER status both CML and CEL levels were higher in ER+ and ER− tumor tissue compared to
non-cancerous but this only reached statistical significance
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for the ER+ comparison (Fig. 1g, h). Collectively these data
show that both CML and CEL are elevated in the tumor of
breast cancer patients and may trend towards higher levels
in ER+ patients.

AGE treatment activates pathways associated
with ER regulation and tamoxifen resistance
We first examined whether AGE stimulates AKT and ERK
activity in ER+ breast cancer cells. Cells were treated with
BSA-AGE (50 μg/mL), and the effects on AKT (ser473)
and ERK phosphorylation (ser202/tyr204) assessed. Control
cells were treated with BSA [17]. We observed a significant
increase in both AKT and ERK phosphorylation in both
MCF7 (Fig. 2a) and T47D (Supplementary Fig. 1a) cell lines
in response to AGE treatment in a time-dependent manner.
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Phosphorylations of ser118 and ser167 within the ligandindependent activation domain of ERα are two residues
emerging as potential predictive markers for patient response
to tamoxifen [19, 20]. MCF7 and T47D cells were treated
with 50ug/mL of AGEs for 30 min and were then examined
for phosphorylation of ERα at residues ser118 and ser167.
100 nM estradiol, one of the key estrogenic ligands for the
receptor, was used as a positive control to ensure optimization of phospho-specific antibodies. In both cell lines and at
both residues, we found a significant increase in phosphorylation of ERα following AGE treatment when compared to
untreated control with no overall change in total ERα levels
(Fig. 1b and Supplementary Fig. 1b). We also examined the
influence of AGE treatment on the phosphorylation of ERα
at ser167 over a time course of 1 h in MCF7 and T47D
cells and observed that the AGE-mediated phosphorylation

Fig. 2  AGE treatment activates
pathways associated with ER
regulation and tamoxifen treatment. a Western blot analysis
of time-dependent AKT and
ERK phosphorylation after
treatment with AGE (50ug/
mL) in MCF7 breast cancer
cells. b Western blot analysis
of ERα phosphorylation after
treatment with AGE (50ug/mL)
in MCF7 breast cancer cells. c
Western blot analysis of AKT
and ERK phosphorylation after
treatment with AGE (50ug/mL)
in MCF7 cells in the presence
of AKT inhibitor. d Western
blot analysis of AKT and ERK
phosphorylation after treatment with AGE (50ug/mL) in
MCF7 cells in the presence of
ERK inhibitor. e Cytotoxicity
assay of MCF7 cell proliferation
after treatment with tamoxifen
(10uM) in the presence of
increasing AGE concentration.
f Cytotoxicity assay of MCF7
cell proliferation after treatment
with tamoxifen (20 μM) in the
presence of increasing AGE
concentration
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of ERα is transient in nature with a peak around 15–30 min
following initial treatment (Supplementary Fig. 1c, d).
To determine if ERK and AKT signaling are required for
AGE-mediated ERα phosphorylation, both ERK and AKT
pathways were pharmacologically inhibited in the presence
of AGE. In MCF7 cells, inhibition of AKT with Ly294002
and inhibition of ERK with the MEK inhibitor U0126 significantly reduced phosphorylation of ERα ser167 (Fig. 2c)
and ser118 (Fig. 2d), respectively, in the presence (50ug/mL)
of AGE metabolite. Similar results were observed in T47D
cells treated in the same manner (Supplementary Fig. 1e, f).
To explore a potential role for AGE metabolites in tamoxifen resistance, we treated MCF7 and T47D cells with varying levels of AGEs in the presence of tamoxifen (10 μM).
Cells were cultured for 24, 48, and 72 h and cell proliferation
was assessed using a sulforhodamine B (SRB) colorimetric
assay [18]. The proliferation of cells in the absence of AGE
was inhibited by treatment with tamoxifen in both cell lines
as expected (Fig. 2e, f). When tamoxifen was added to the
cells in the presence of increasing concentration of AGE
(from 5 to 50 μg/ml), a dose-dependent restoration of proliferation was observed in both MCF7 and T47D cells (Fig. 2e,
f). The data outlined in Fig. 2 identify a mechanistic link
between sugar-derived metabolites, AGEs, and ERα regulation which may provide a direct biological consequence of
poor lifestyle that may directly impact tamoxifen efficacy.

Lifestyle intervention reduces the levels of AGE
in the circulation of ER+ breast cancer survivors
In a proof of concept pilot study, we tested the ability of
a defined lifestyle intervention to lower AGE levels in ten
overweight/obese post-menopausal women with non-metastatic stage I–III ER+ breast cancer. Characteristics for the
ten participants are summarized in Table 1. The intervention consisted of a focused 11-week physical activity (PA)
and dietary counseling intervention that took place within
the established clinical setting of the Medical University
of South Carolina (MUSC) cardiopulmonary rehabilitation
center (Cardiac-Rehab) (Fig. 3a) (Supplementary Methods).
The pilot study showed a favorable 67% consent rate. Of
the 15 enrolled patients, 12 completed the 11-week program;
2 participants were later found to be ineligible because of
past weight loss surgery that was not reported at enrollment
(and were not included in this analysis). A further 3 dropped
out due to competing medical conditions and unwillingness to continue resulting in a 73% adherence rate. Overall
adherence to the weekly exercise sessions at cardiac rehab
was 82.3% with 50% of participants showing 100% adherence to the twice weekly visits. A modest but general trend
of improvement was observed in clinical and laboratory
measures as a result of the 11-week intervention (Table 2
and Supplementary Table 1). Statistical significance was
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observed for diastolic blood pressure (p = 0.01) and lipid
levels (p = 0.05). An analysis of the Fitbit data showed a
significant increase in overall very active minutes (Fig. 3b)
which coincided with a concurrent increase in average calories burned (Fig. 3c) when compared to baseline assessments, demonstrating the potential health benefits of the
study intervention for cancer survivors. Seven (70%) participants showed reduced calorie intake as a result of the
dietary intervention while three (30%) increased their calorie
intake (Fig. 3d). While some participants showed individual
reductions (Supplementary Fig. 2a–c), an analysis of aggregate diet composition showed no significant difference in
fat, carbohydrate, and protein composition (Supplementary
Fig. 2d). Maximal oxygen consumption (VO2 max) was
significantly increased at the end of the intervention when
compared to baseline levels (Fig. 3e). An assessment of daily
dietary-AGE content was carried out on the basis of 7-day
food records; the assessment was estimated from a database
of ~ 560 foods and was expressed as AGE Equivalents (Eq/
day) (1 AGE equivalent = 1000 kilounits) [21]. Dietary-AGE
content was consistently reduced in the participants taking
part in the intervention (Fig. 3f). Compared to baseline values, nine participants (90%) showed significant reductions
in dietary-AGE intake at week 8, which maintained at week
11 for eight participants (80%). In general, participants that
showed significant reductions in dietary-AGE intake at
week 8 and week 11 also showed significant reductions in
circulating AGE levels when fasting serum samples were
analyzed by ELISA (Fig. 4a). Only two patients had higher
circulating AGE levels at week 11 than baseline. Median
AGE levels at baseline were 53ug/ml compared to 23ug/ml
at week 8 and 38 μg/ml at week 11 (Fig. 4b). These findings
represent an about 30–60% reduction in the AGE levels.
An examination of circulating AGE levels at 13 weeks post
intervention (24 weeks) showed a return to pre-intervention
levels in all participants (Fig. 4C). Interleukin 6 (IL6) and
C-reactive protein (CRP) are often used to assess inflammatory changes induced by diet and exercise. An analysis
of IL6 (Fig. 4d) and CRP (Fig. 4e) levels by ELISA in the
same AGE-assessed samples revealed no significant differences at any time point.

Discussion
Given the increasing consumption of dietary-AGEs due
to their inherent relationship with a Western lifestyle, it is
important to elucidate their potential contribution to the carcinogenic process. Lifestyle and pharmacological interventions that lower AGE levels may then be viable options to
reduce breast cancer incidence and improve prognosis in
those living with breast cancer. We have identified a mechanistic link between AGEs and ERα regulation which may
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Table 1  Participant information
for the lifestyle intervention
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Characteristic

n (%)

Age, mean (range)
Age at diagnosis, mean (range)
Race
European American
African American
Education level
< 12 years
High school graduate or GED
Some college
College graduate
Postgraduate
Diabetes
Yes
No
Time since diagnosis (from date of study registration)
1–6 months
7–12 months
13–18 months
19–24 months
25–36 months
Tumor stage
IA
IIA
IIB
IIIA
Menopausal status
Pre-menopausal
Post-menopausal
Hormone status
ER/PR+ Her2−
Treatment type all participants had had surgery apart from 1
Radiation therapy only
Hormone therapy only
Radiation therapy + chemotherapy
Radiation therapy + hormone therapy
Radiation therapy + chemotherapy + hormone therapy

56 (46–68) years
57 (46–67) years
6 (60)
4 (40)
1 (10)
1 (10)
5 (50)
1 (10)
2 (20)
1 (10)
9 (90)
4 (40)
5 (50)
0 (0)
0 (0)
1 (10)
5 (50)
2 (20)
2 (20)
1 (10)
1 (10)
9 (90)
10 (10)
1 (10)
1 (10)
1 (10)
4 (40)
3 (30)

Table of patient characteristics
GED general education development, ER estrogen receptor, PR progesterone receptor, HER human EGF
receptor

provide a direct biological consequence of poor lifestyle that
may directly impact tamoxifen efficacy.
About 70% of all invasive breast cancers express the
estrogen receptor, making it of utmost importance to create more effective treatments, reduce resistance to current
treatments, and improve outcomes through lifestyle interventions for these patients. The data presented suggest that
AGE levels may be highest in ER+ tumors when compared
to ER− and that, at least in vitro, elevated AGE levels can
inhibit the growth inhibitory effects of tamoxifen. Studies

have shown an association between certain estrogenindependent phosphorylation sites on ERα and tamoxifen
resistance [19, 20]. Here, we have shown that two of these
residues, ser118 and ser167, are activated in response to
AGE exposure and that AGE treatment reduces cell sensitivity to tamoxifen treatment. By identifying an AGEmediated effect on sensitivity to this drug, we can add to
the existing knowledge base that is reinforcing the need for
more personalized medicine in cancer, including implementation of specific lifestyle changes. By characterizing
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◂Fig. 3  Lifestyle

intervention reduces dietary-AGE intake in
ER+ breast cancer survivors. a Conceptual Framework for the PA
and dietary intervention. b Average very active minutes achieved
by participants during the 11-week lifestyle intervention as assessed
from Fitbit data. c Average calories burned by participants during the 11-week lifestyle intervention as assessed using 7-day food
records. d Calorie intake for each participant as assessed using 7-day
food records. e Average VO2 max at baseline and completion of the
11-week lifestyle intervention. f Dietary-AGE intake per participant at baseline, week 8, and week 11 of the lifestyle intervention as
assessed using 7-day food records

a functional role of AGEs in the development of tamoxifen resistance, we suggest that targeted therapies for this
type of cancer can potentially become more effective
through modification of diet, increased physical activity,
and/or through pharmacological strategies to reduce AGE
accumulation. While this in vitro work is an important
foundation in investigating a role for AGEs in tamoxifen
resistance, it fails to address the complexity of the tumor
microenvironment and intracellular signaling. However,
it is still an important first step and future studies will
address the importance of AGE in mediating resistance to
tamoxifen especially when those studies use in vivo mouse
models to validate the AGE-mediated effects we observed
in our cell line studies.
Many of the foods that we consume contribute to the
AGE accumulation pool in the body [21–24]. The Western
lifestyle consisting of foods high in sugar, protein, and fat
and low in fruit, grains, and vegetables is particularly AGE
laden and associated with an increased chronic disease risk
[21–24]. AGE and AGE precursors are naturally present in
uncooked meats; frying, grilling, or roasting leads to a significant increase in AGE formation as we cook our foods
[5, 6]. Similarly, food processing and manufacturing also
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accelerates AGE formation and food manufacturers regularly
add AGEs directly during processing in order to improve
food appearance and taste 21.
A major goal of the proof of concept lifestyle intervention
was to assess the clinical infrastructure of cardiac rehab as
a platform for breast cancer survivors. This clinical setting
was chosen because the goal of cardiac rehab is to provide
supervised exercise training to enable patients with cardiovascular disease to achieve their optimal physical functioning [25–27]. The study shows a favorable 67% consent rate
and 73% adherence rate and resulted in an increased level
of PA, promoted a healthier diet, and was shown to be a
successful strategy for reducing circulating AGE levels in
breast cancer patients. This study identifies AGEs as a ubiquitous molecular indicator of lifestyle change. Both dietary
and circulating AGE levels were consistently lowered by
the cardiac rehab lifestyle intervention, while we observed
no change in the more recognized bio-behavioral markers
IL6 and CRP.
In summary, AGE metabolite levels may represent a sensitive ubiquitous bio-behavioral marker for the molecular
assessment of lifestyle change. Dietary-AGE restriction has
been previously shown to reduce circulating AGE levels in
patients with chronic kidney disease, metabolic syndrome,
and diabetes [28]. As the intervention for this study was a
proof of concept exercise, the results should be interpreted
with caution due to a number of limitations including the
small cohort of participants in the intervention which limits the ability to make conclusions beyond the feasibility of
the intervention. However, the present study may provide
a defined framework for future studies seeking to improve
cancer outcomes and quality of life among cancer survivors
across wide racial/ethnic, geographic, and socioeconomic
strata.
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Table 2  Average pre- and post- intervention clinical and laboratory characteristics

Clinical characteristics
Height (cm)
Weight (kg)
Pulse (bpm)
Respiratory rate (bpm)
Waist circumference (cm)
Hip circumference (cm)
Waist:hip ratio (cm)
Body mass index (kg/m2)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Laboratory characteristicsa
Glucose (mg/dl)b
Insulin (mcILI/m1)c
Lipid Levels (mmol/L)d
Hemoglobin A1C (mmolimo1)e
HOMA-insulin resistancef,g

Pre-intervention mean (range)

Post-11-week intervention
mean (range)

Paired difference
mean

164.3 (160.0–172.7)
90.9 (75.3–110.3)
80 (67–95)
17 (16–20)
107.0 (94.0–124.0)
116.7 (106.7–125.0)
0.90 (0.83–0.95)
33.8 (27.5–43.09)
137 (117–166)
84 (74–100)

164.3 (160.0–172.7)
89.5 (71.5–109.5)
77 (62–88)
18 (16–20)
105.6 (91.4–125.1)
116.8 (108–141.0)
0.90 (0.83–1.02)
33.2 (26.4–42.8)
129 (112–144)
76 (62–94)

0.0
− 1.4
− 2.9
+0.9
− 1.1
0.1
0.0
− 0.5
− 7.3
− 8.2

0.34
0.31
0.17
0.50
0.97
0.55
0.30
0.06
0.01

117 (92–139)
24.4 (11.7–43.8)
200 (166–234)
6.1 (5.1–7.6)
7.2 (3.5–15.0)

117 (102–141)
17.1 (9.1–31.4)
186 (146–236)
6.0 (5.3–7.2)
5.1 (2.8–10.2)

+ 1.1
− 4.5
− 10.6
− 0.1
− 1.6

0.65
0.09
0.049
0.65
0.11

The bold numbers are statisticaly significant
Table of clinical and laboratory measures taken during the intervention
a

b
c
d
e
f

24-h fasting blood draws
Glucose: pre-intervention missing = 1 (n = 9)
Insulin: pre-intervention missing = 3 (n = 7); post-intervention missing = 1 (n = 9)
Lipid levels: post-intervention missing = 1 (n = 9)
Hemoglobin A1C: post-intervention missing = 1 (n = 9)

HOMA-insuling resistance: pre-intervention missing = 4 (n = 6); post-intervention missing = 1 (n = 9)

g

HOMA-Insulin resistance formula: (insulin × glucose)∕ 405
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p value
(paired t
test)
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Fig. 4  Lifestyle intervention
reduces the levels of AGE in
the circulation of ER+ breast
cancer survivors. a Circulatory
AGE levels per participant at
baseline, week 8 and week 11
of the lifestyle intervention as
assessed by ELISA. b Average
AGE levels at baseline, weeks 8
and 11 for all participants of the
lifestyle intervention as assessed
by ELISA. c Percent change
in circulating AGE levels at
baseline, weeks 8 and 11 for all
participants at of the lifestyle
intervention and 13 weeks after
the intervention had ended as
assessed by ELISA. d Average IL6 levels at baseline and
at completion for all participants of the 11-week lifestyle
intervention as assessed by
ELISA. e Average CRP levels at
baseline and at completion for
all participants of the 11-week
lifestyle intervention as assessed
by ELISA
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